Sunshine Biopharma Files 8-K

TL;DR

SBFM filed an 8-K for an 'Other Event' on 9/9. Details TBD.

AI Summary

Sunshine Biopharma, Inc. filed an 8-K on September 10, 2024, reporting an "Other Event" that occurred on September 9, 2024. The filing does not contain specific details about the event itself, only the reporting date and the nature of the filing.

Why It Matters

This filing indicates a material event has occurred for Sunshine Biopharma, Inc., requiring public disclosure, though the specifics are not yet detailed.

Risk Assessment

Risk Level: medium — The filing of an 8-K often signals significant corporate events, but the lack of detail in this specific filing creates uncertainty.

Key Numbers

• 001-41282 — Commission File Number (Identifies the company's SEC filing history)
• 20-5566275 — IRS Employer ID No. (Company's tax identification number)

Key Players & Entities

• Sunshine Biopharma, Inc. (company) — Registrant
• September 9, 2024 (date) — Date of earliest event reported
• September 10, 2024 (date) — Date of report
• 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale , FL 33301 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC

Filing Documents

• sunshine_8k.htm (8-K) — 27KB
• 0001683168-24-006281.txt ( ) — 244KB
• sbfm-20240909.xsd (EX-101.SCH) — 3KB
• sbfm-20240909_def.xml (EX-101.DEF) — 29KB
• sbfm-20240909_lab.xml (EX-101.LAB) — 36KB
• sbfm-20240909_pre.xml (EX-101.PRE) — 26KB
• sunshine_8k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On September 9, 2024, Sunshine Biopharma, Inc. (the "Company") received a letter from the Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the bid price requirement in Listing Rule 5550(a)(2) (the "Bid Price Rule"), as required by the Hearing Panel's ("Panel") decision dated June 28, 2024. The letter further states that the Company will be subject to a Mandatory Panel Monitor for a period of one year. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff ("Nasdaq Staff") finds the Company again out of compliance with the Bid Price Rule, the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, the Nasdaq Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C). The Company's securities may be delisted from Nasdaq at that time. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 10, 2024 SUNSHINE BIOPHARMA, INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR